Double-Blind, Four Week Trial Of [S,S]-Reboxetine And Atomoxetine In Adults With Attention Deficit Hyperactivity Disorder.

Pfizer

Status and phase: Withdrawn; Phase 2

Conditions: Attention Deficit Hyperactivity Disorder

Treatments: Drug: Atomoxetine; Drug: PNU-165442G; [S,S]-reboxetine

Study type: Interventional

Funder types: Industry

Identifiers

NCT00562055

A6061060

Details and patient eligibility

About

This study will compare the safety and efficacy of [S,S]-reboxetine to atomoxetine in the treatment of adult patients with attention deficity-hyperactivity disorder.

Sex: All

Ages: 18 to 55 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Diagnosis of Attention Deficit Hyperactivity Disorder according to DSM-IV criteria.
2. Score of 24 or higher on the Adult ADHD Investigator Symptom Rating Scale
3. Score of 4 or higher on the Clinician Global Impression - Severity scale

Exclusion criteria

1. Significant comorbid psychiatric diagnoses
2. Significant risk of suicidal or violent behavior

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

0 participants in 2 patient groups

Arm A

Experimental group

Treatment:

Drug: PNU-165442G; [S,S]-reboxetine

Arm B

Active Comparator group

Treatment:

Drug: Atomoxetine